Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122620) titled 'A Single-Arm, Single-Center Clinical Study of Iparomlimab and Tuvonralimab combined with Lenvatinib and TACE/HAIC for the Treatment of Unresectable Hepatocellular Carcinoma' on April 15.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Unresectable Hepatocellular Carcinoma
Recruitment Status: Recruiting
Phase: 4
Date of First Enrollment: 2026-04-15
Target Sample Size: Treatment Group:34;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=309192
Published by HT Digital Conte...